Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204.

"This rat study, along with the GLP study on dogs, are the last two key studies we need to complete before entering phase 1 human clinical testing of our lead asset - MB-204," said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. "We are also in the final preparation stage of initiating the 4-week dose-ranging GLP studies on dogs and will update our shareholders on our progress shortly."

"We look forward to completing these two critical studies of MB-204 and entering human trials in the coming months, which is an important value-creating milestone for Marvel and our shareholders," said Rod Matheson, CEO of Marvel Biosciences. "MB-204 to date has shown very promising results, and we believe that this asset has the potential to reduce symptoms of depression and Alzheimer's, both of which are significant and growing problems. We look forward to advancing our lead asset MB-204 through human trials and playing a pivotal role in addressing this growing addressable market."

In the United States, it is estimated that one in ten senior citizens over the age of 65 suffer from dementia. MB-204 is a novel solution to Alzheimer's that has similar properties to the Food and Drug Administration-approved drug, Istradefylline. MB-204 has, through the Company's studies, proven to be more effective and longer lasting than Istradefylline in pre-clinical studies.

MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration.

About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/157765

News Provided by Newsfile via QuoteMedia

MRVL
The Conversation (0)
Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience

The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders including: Dave Barr, Sharon Wang, Paul Andreola, Becky Popoff, Harold Leishman, Sean MacGillis, and more!

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience

The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders including: Dave Barr, Sharon Wang, Paul Andreola, Becky Popoff, Harold Leishman, Sean MacGillis, and more!

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
CSE:NUR

NuRAN Wireless Reports Audited Annual Financial Results

NuRAN Wireless Inc. (“NuRAN Wireless” or the “Company”) (CSE:NUR) (OTC:NRRWF) (FSE:1RN) , a leading supplier of mobile and broadband wireless solutions to connect the next billion, is pleased to announce its audited financial results for the twelve months ended October 31, 2018. All dollar amounts are expressed in Canadian currency.

NuRAN Wireless Inc.-Technology Leadership in the Making

Keep reading...Show less
Charbone Hydrogene annonce la reception de 371 150 $ provenant de l'exercice de bons de souscription et d'autres mises a jour corporatives

Charbone Hydrogene annonce la reception de 371 150 $ provenant de l'exercice de bons de souscription et d'autres mises a jour corporatives

(TheNewswire)

Charbone Hydrogen Corporation

Brossard, Québec TheNewswire - le 13 décembre 2024 - CORPORATION CHARBONE HYDROGÈNE (TSXV: CH OTCQB: CHHYF, FSE: K47 ) (« Charbone » ou la « Société »), la seule société d'Amérique du Nord cotée en bourse spécialisée dans l'hydrogène vert, est heureuse d'annoncer qu'elle a reçu 371 150 $ provenant de l'exercice de bons de souscription expirant en décembre 2024 ainsi qu'en février 2025.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
CHARBONE Hydrogen Announces Receipt of $371,150 from warrant exercises and Other Corporate Updates

CHARBONE Hydrogen Announces Receipt of $371,150 from warrant exercises and Other Corporate Updates

(TheNewswire)

Charbone Hydrogen Corporation

Brossard, Québec TheNewswire - December 13, 2024 Charbone Hydrogen Corporation (TSXV: CH; OTCQB: CHHYF; FSE: K47) (the "Company" or "CHARBONE"), North America's only publicly traded pure-play green hydrogen company, is pleased to announce that it has received $371,150 from the exercise of warrants expiring in December 2024 as well as February 2025.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Veritiv Completes Acquisition of Orora Packaging Solutions

Veritiv Operating Company, a leader in specialty packaging distribution, today announced it has completed its acquisition of Orora Packaging Solutions (OPS). 1

On September 3, 2024 , Veritiv announced it had entered into a binding agreement with Orora (ASX: ORA) to acquire their North American packaging and distribution business Orora Packaging Solutions.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Troy Minerals Submits Drilling Permit Application for Table Mountain Silica Project, British Columbia

Troy Minerals Submits Drilling Permit Application for Table Mountain Silica Project, British Columbia

Troy Minerals Inc. ("Troy" or the "Company") (CSE:TROY)(OTCQB:TROYF)(FSE:VJ3) is pleased to announce the submission of a drilling permit application for the Table Mountain Silica Project in British Columbia. This key milestone supports Troy's strategic plan to evolve from an exploration-focused company into a revenue-generating mining operation, with production anticipated in the near term

The permit application details a comprehensive drilling program, requesting approval for a program involving up to 34 drill holes in 2025, totaling approximately 1,700 meters of drilling in the first year, and an additional 20 holes planned in subsequent years, bringing the total to approximately 2,700 meters over the proposed five-year period, with provisions for additional exploration activities as needed. This phased approach enables Troy to methodically advance the Table Mountain project, ensuring alignment with both operational goals and market demand.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Hempalta Corp. Completes 100% Acquisition of Hemp Carbon Standard, Expanding Company's Leadership in Hemp Carbon Credits

Hempalta Corp. Completes 100% Acquisition of Hemp Carbon Standard, Expanding Company's Leadership in Hemp Carbon Credits

Acquisition strengthens Hempalta's capacity to scale carbon credit solutions while establishing strategic foundation for advancing biochar expansion initiatives

Hempalta Corp. (TSXV: HEMP) ("Hempalta" or the "Company") today announced its acquisition of the remaining 49.9% of Hemp Carbon Standard Inc. ("HCS"), granting Hempalta full ownership of the carbon credit platform.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Canadian Investment Regulatory Organization Trade Resumption - CH

Canadian Investment Regulatory Organization Trade Resumption - CH

Trading resumes in:

Company: Charbone Hydrogen Corporation

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×